The reduction in price target by a prominent analyst like Goldman Sachs can lead to negative sentiment among investors, potentially causing a short-term decrease in BioNTech's stock price. The Neutral rating indicates no expected significant upward or downward movement from the stock's current price level, but the lowered target suggests a reassessment of the stock's value potential, which could impact investor confidence.